• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·1733.TW
Share

Apex Biotechnology Corp. Stocks

NT$ 29.35Last Updated 24.06.2026

Issuer Rating

4/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 92.48M

NT$ 29.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Apex Biotechnology Corp. is a Taiwanese firm that specializes in the global development, manufacturing, and distribution of medical devices designed for home use, all powered by sophisticated biosensor technology. Their comprehensive product lineup features a variety of personal health monitoring systems, including those for tracking blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1c, and ketone levels. In addition, the company provides self-testing solutions for coagulation and multi-parameter analysis, alongside advanced hemoglobin screening systems. Beyond patient diagnostics, Apex Biotech also offers systems for detecting pesticide residues. The company further extends its services to include digital care management and telehealth platforms. Established in 1997, Apex Biotechnology Corp. operates from its headquarters located in Hsinchu City, Taiwan.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 13:03

Elon Musk Is No Longer a Trillionaire — Bloomberg

24.06.2026 11:37

Mag7 shares have experienced their biggest sell-off in over a year. What's next?

24.06.2026 10:35

Top Stories This Morning: Asia Recovers After Sell-Off, SpaceX Raises $25 Billion

24.06.2026 09:00

Apollo and Morgan Stanley have once again restricted withdrawals from private credit funds

24.06.2026 08:00

Alibaba has filed a lawsuit against the Pentagon over allegations of ties to the Chinese military

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026